EncounterPRO receives SureScripts certification
ATLANTA WiFiMed Holdings announced that its subsidiary EncounterPRO Healthcare Resources has successfully completed the comprehensive testing and certification process for SureScripts certification and is now a SureScripts Certified Solution Provider.
Now being certified, physicians who use the EncounterPRO Electronic Health Record product can now connect to SureScripts’ Pharmacy Health Information Exchange, which is certified in 95 percent of all pharmacies in the United States.
“We are very pleased to have become a SureScripts Certified Solution Provider,” said Greg Vacca, chief executive officer of WiFiMed Holdings. “The unique workflow engine of EncounterPRO EHR will help set it apart from any other product in the market as it will take e-prescribing to a new level of convenience for both physicians and patients. SureScripts certification enables EncounterPRO physicians and users to send new prescriptions to a patient’s pharmacy, receive renewal requests back and send renewal approvals directly from within EncounterPRO EHR, making the prescription process much safer and more efficient.”
Pfizer wins Celebrex patent challenge
NEW YORK Pfizer announced that the Court of Appeals for the Federal Circuit has upheld two main patents for the company’s anti-inflammatory drug Celebrex, according to published reports.
Teva had challenged the patents, but the court ruled that the patents are valid and enforceable, but they did rule that a third patent, covering the treatment of inflammation was invalid.
Nevertheless, the decision blocks Teva from launching a generic version until May 2014.
The drug had global sales of $1.7 billion in 2007. Bear Stearns analyst project that it will reach global sales of $2.5 billion in 2008, an increase of 9 percent, and that the drug will pull in $3.1 billion by 2012.
FDA to enhance warnings on Tussionex
WASHINGTON UCB, the maker of Tussionex cough medicine, has reached out to the Food and Drug Administration to place a stronger warning on the drug. This new push stems from the report of five deaths of young children from taking Tussionex.
According to published reports, the deaths were all children under age 6, but the Belgian pharmaceutical company said that the drug is only to be taken for children and adults ages 6 and up.
Tussionex Pennketic Extended- Release Suspension contains the pain reliever hydrocodone. According to reports, the FDA is planning to issue an alert about the effects of Tussionex.